Literature DB >> 11007687

Effect of apolipoprotein E polymorphism on serum lipid, lipoproteins, and atherosclerosis in hemodialysis patients.

G Güz1, F Nurhan Ozdemir, S Sezer, I Işiklar, Z Arat, M Turan, M Haberal.   

Abstract

Atherosclerosis and cardiovascular disease are the main causes of death in hemodialysis patients. Possession of the apolipoprotein E4 (ApoE4) allele has been associated with increased levels of serum lipids and with coronary and carotid artery atherosclerosis. We investigated the possible relationship between ApoE polymorphism and atherosclerosis risk factors in hemodialysis patients. Two hundred sixty-nine hemodialysis patients (115 women, 154 men) were included in our study. The mean patient age and mean hemodialysis duration were 45.8 +/- 15.3 years and 52.6 +/- 40.6 months, respectively. Testing was done on all patients to determine ApoE genotype and serum levels of total cholesterol (T-Cho), low-density lipoprotein (LDL-C), high-density cholesterol (HDL-C), triglyceride (TG), lipoprotein (a) (Lp[a]), intact parathormone (iPTH), and fibrinogen. ApoE genotype was identified with the polymerase chain reaction. Ultrasonographic measurement of carotid artery intima media thickness (IMT) was used to diagnose atherosclerosis. We also analyzed ApoE polymorphism and risk factors such as age, gender, duration of hemodialysis, smoking, and hypertension in relation to the presence of atherosclerosis. Serum T-Cho and LDL-C levels were higher in patients with the ApoE4/3 phenotype than in those with ApoE3/3 and ApoE3/2 phenotypes (P < 0.05). However, there was no statistically significant link between ApoE polymorphism and serum levels of TG, HDL-C, or Lp(a) (P > 0.05). Apart from a relationship with age and duration of hemodialysis (P < 0.05), we found no significant association between atherosclerosis and ApoE polymorphism or the other risk factors analyzed (P > 0.05). In conclusion, although ApoE polymorphism significantly affects serum levels of T-Cho and LDL-C in hemodialysis patients, this study indicates that ApoE polymorphism is not associated with the presence of atherosclerosis in these individuals. The high incidence of atherosclerosis in these patients underlines the need for further research on other possible causative factors.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11007687     DOI: 10.1053/ajkd.2000.17682

Source DB:  PubMed          Journal:  Am J Kidney Dis        ISSN: 0272-6386            Impact factor:   8.860


  6 in total

1.  Could apolipoprotein E polymorphisms be hidden behind the relation between bone mineral density and atherosclerosis in hemodialysis patients?

Authors:  Evagelos N Liberopoulos; Moses S Elisaf
Journal:  Osteoporos Int       Date:  2003-10-30       Impact factor: 4.507

2.  Apolipoprotein E polymorphism in hemodialyzed patients and healthy controls.

Authors:  Jaroslav A Hubacek; Silvie Bloudickova; Ruzena Kubinova; Hynek Pikhart; Ondrej Viklicky; Martin Bobak
Journal:  Biochem Genet       Date:  2009-06-30       Impact factor: 1.890

Review 3.  Dietary lipids in the aetiology of Alzheimer's disease: implications for therapy.

Authors:  Janelle L Cooper
Journal:  Drugs Aging       Date:  2003       Impact factor: 3.923

Review 4.  Association between apolipoprotein E genotype and carotid intima-media thickness may suggest a specific effect on large artery atherothrombotic stroke.

Authors:  Lavinia Paternoster; Nahara Anáni Martínez González; Steff Lewis; Cathie Sudlow
Journal:  Stroke       Date:  2007-12-06       Impact factor: 7.914

5.  Association of apoE gene polymorphisms with lipid metabolism in renal diseases.

Authors:  Tianbiao Zhou; Hongyan Li; Hongzhen Zhong; Zhiqing Zhong; Shujun Lin
Journal:  Afr Health Sci       Date:  2020-09       Impact factor: 0.927

Review 6.  Apolipoprotein E gene variants on the risk of end stage renal disease.

Authors:  Cheng Xue; Wei Nie; Dan Tang; Lujiang Yi; Changlin Mei
Journal:  PLoS One       Date:  2013-12-13       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.